as 12-27-2024 2:39pm EST
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
Founded: | 2000 | Country: | United States |
Employees: | N/A | City: | Rockville |
Market Cap: | 257.3M | IPO Year: | 2013 |
Target Price: | $7.17 | AVG Volume (30 days): | 477.0K |
Analyst Decision: | Hold | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.56 | EPS Growth: | N/A |
52 Week Low/High: | $2.95 - $21.88 | Next Earning Date: | 11-05-2024 |
Revenue: | $141,329,000 | Revenue Growth: | 16.68% |
Revenue Growth (this year): | 174.73% | Revenue Growth (next year): | -50.72% |
MGNX Breaking Stock News: Dive into MGNX Ticker-Specific Updates for Smart Investing
GlobeNewswire
25 days ago
Simply Wall St.
25 days ago
MT Newswires
2 months ago
Simply Wall St.
2 months ago
GlobeNewswire
2 months ago
Thomson Reuters StreetEvents
2 months ago
GuruFocus.com
2 months ago
Motley Fool
2 months ago
The information presented on this page, "MGNX MacroGenics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.